US ERA ARCHIVE DOCUMENT

X016

DIPHENYLAMINE

REVIEW AND EVALUATION OF ADI

Prepared by: David W. Hohreiter

Center for Chemical Hazard Assessment Syracuse Research Corporation Syracuse, NY 13210

Internal Review: P.F. Goetchius Editor: C. Adair

Contract No. 68-03-3228 Task 14

Prepared for:
Environmental Criteria and Assessment Office
U.S. Environmental Protection Agency
Cincinnati, OH 45268

Ms. Helen Ball, Project Officer Dr. Christopher DeRosa, Technical Project Monitor

September 24, 1985

LIST OF ABBREVIATIONS

ADI Acceptable daily intake

NOAEL No-observed-adverse-effect level

NOEL No-observed-effect level

ppm Parts per million

TLV Threshold limit value

1. REVIEW AND EVALUATION OF ADI

1.1. REVIEW OF ADI

The Environ, Inc. (1984) ADI for diphenylamine is 0.05 mg/kg/day (uncertainty factor=100) and was derived from a rat subchronic to chronic oral NOEL from an unspecified study in which higher doses caused renal cysts. The ADI was taken from the U.S. EPA (1984) list of ADIs that cited an earlier U.S. EPA (1982) document in which an ADI of 3.6 mg/day for a 70 kg human (0.051 mg/kg/day) was derived from the TLV, however, the U.S. EPA (1985) list of ADIs reports only an interim ADI of 0.031 mg/kg/day. This ADI is based on a rat chronic oral NOEL of 3.1 mg/kg/day where higher doses caused renal cysts. The NOEL was reported to be 3.1 mg/kg/day by U.S. EPA (1985) and was attributed to a study by Thomas et al. (1967a). An uncertainty factor of 100 was applied. In this study, groups of 40 weanling albino rats (Slonaker-Addis strain, 20/sex) were fed diets containing 0, 0.001, 0.01, 0.1, 0.5 and 1.0% diphenylamine for 2 years. Depressed growth attributed to significantly lower food consumption occurred at the two highest doses. A slight inhibition of growth apparently caused by diphenylamine and not by lower food consumption, occurred in females at the 0.1% level. Rats receiving \geq 0.1% diphenylamine exhibited kidney lesions, (i.e., cystic dilatation of renal tubules with interstitial inflammation). lected hematological parameters, measured in control and high dose rats at intervals up to day 463 of exposure, were not affected by treatment and treatment appeared to have no effect on survival. No adverse effects were observed in rats receiving dietary concentrations of \geq 0.01% diphenylamine. At this dietary level, U.S. EPA (1985) appears to have calculated a dose of 3.1 mg/kg/day for rats from body weight and food consumption data provided by the investigators.

1.2. OTHER RELEVANT INFORMATION

Diphenylamine is a fungicide which causes effects similar to those of clinical polycystic kidney disease in mammals. As described by Smith et al. (1985), several studies reported toxic effects when diphenylamine was administered in the diet of rats at concentrations of $\geq 1\%$ Since these studies will not affect the risk assessment, they will not be discussed; however, studies that reported toxic effects and NOAELs at lower doses will be discussed.

Thomas et al. (1957) reported toxic effects (growth inhibition, renal tubule dilatation) in rats exposed to dietary concentrations of $\geq 0.5\%$ diphenylamine. These effects were not observed in rats receiving 0.025 or 0.1% diphenylamine.

Coulston et al. (1971) fed mice diets containing 0, 50, 100 and 250 ppm for up to 92 weeks. They observed increased spleen weights, increased hemosiderosis in spleens, and increased numbers of blood reticulocytes, evidence of increased erythrócytopoiesis in the highest dose group. Dose related increases in Heinz bodies in red blood cells also occurred at concentrations of \geq 50 ppm; however, the biological significance of this effect in the absence of hematological changes is uncertain (Smith et al., 1985).

Thomas et al. (1967b) conducted an experiment in which groups of four beagle dogs were fed diets containing 0, 0.01, 0.1 or 1.0% diphenylamine for 2 years. In dogs receiving the highest dose, adverse effects included fatty changes in the liver, hemosiderosis in the spleen, bone marrow and kidneys, and an increase in kidney weight. Dogs fed 0.1 or 1.0% diphenylamine exhibited depressed growth and anemia; however, no toxic effects were observed at 0.01%. The authors reported that at the end of the study, the two female

dogs receiving 0.01% diphenylamine had each consumed 14 g diphenylamine or 1.54~g/kg. Dividing this value by 730 days, the duration of the study, results in an ADI of 2.11 mg/kg/day.

There is no evidence available that indicates that diphenylamine is carcinogenic. No increase in tumor incidence occurred in the chronic feeding studies in rats (Thomas et al., 1967a) or mice (Coulston et al., 1971. A combined in vivo/in vitro bioassay for neoplastic transformation in hamsters yielded negative results for diphenylamine but positive results for known carcinogens. Diphenylamine was also negative in several mutagenicity assays using bacteria and cultured mammalian cells, as summarized by Smith et al. (1985). Diphenylamine, however, may be converted to carcinogenic nitrosamines in the stomach by reaction with nitrite. N-nitrosodiphenylamine has been found to cause urinary bladder carcinomas in rats. A common impurity of diphenylamine, 4-aminobiphenyl, is also considered a carcinogen (IARC, 1972). Diphenylamine has not been scheduled for testing by the National Toxicology Program (NTP 1985).

There is little information available concerning the possible teratogenic effects of diphenylamine. Pregnant rats received diphenylamine in the diet (1.5 or 2.5%) or by gavage for the last 7 days of gestation (Crocker et al., 1972). Although dams were unaffected, cystic lesions occurred in the proximal nephrons of offspring. The severity of the lesions decreased greatly when purified diphenylamine was used, and a purified contaminant of commercial diphenylamine produced similar lesions. Therefore, the authors concluded that this contaminant rather than diphenylamine might be the nephrotoxic component of commercial diphenylamine.

ACGIH (1984) lists a TLV for diphenylamine in the atmosphere of $10\ mg/m^3$.

1.3. EVALUATION OF ADI

The ADI of 0.05 mg/kg/day listed by Environ, Inc. (1984) for diphenylamine should be rejected because Environ, Inc. (1984) cited the U.S. EPA (1984) list of ADIs which erroneously reported that the ADI was based on the Thomas et al. (1967a) study in rats rather than on the human TLV. The U.S. EPA (1985) reported an ADI of 0.031 mg/kg/day based on the rat NOEL of 3.1 mg/kg/day (Thomas et al., 1967a) with an uncertainty factor 100. Apparently, the U.S. EPA (1985) calculated the dose of 3.1 mg/kg/day from body weight and food consumption data provided by the investigators. Since long-term data in mice (Coulston et al., 1971) and dogs (Thomas et al., 1967b) support the NOEL in the rat study, the ADI of 0.031 mg/kg/day (2.17 mg/day for a 70 kg human) calculated by the U.S. EPA (1985) is recommended as the provisional ADI for diphenylamine.

2. REFERENCES

ACGIH (American Conference of Governmental Industrial Hygienists). 1984. TLVs - Threshold limit values for chemical substances and physical agents in the workroom environment with intended changes for 1984-1985. ACGIH, Cincinnati, OH. p. 18.

Coulston, F., L. Golberg, R. Abraham and K.F. Benitz. 1971. Long-term study of the toxicity of diphenylamine in mice. Final report (unpublished). Inst. Exp. Pathol. Toxicol., Albany Medical College, Albany, NY. (Cited in Smith et al., 1985).

Crocker, J.F.S., D.M. Brown, R.F. Borch and R.L. Vernier. 1972 Renal cystic disease induced in newborn rats by diphenylamine derivatives. Am. J. Path. 66: 343-348.

Environ, Inc. 1984. A list of ADIs and q_1*s prepared under contract to the U.S. EPA.

IARC (International Agency for Research on Cancer). 1972. IARC Monographs on the evaluation of Carcinogenic Risk of Chemicals to Man. 4-Aminobiphenyl. IARC Vol. 1. Lyon, France, WHO p. 74-79.

NTP (National Toxicology Program). 1985. Management Status Report. 8/7/85.

Smith, J.W., W.M. Meylan, J.M. Becker and S.B. Wilbur. 1985. Health and Environmental Effects Profile on N,N-diphenylamine. Prepared by Syracuse Research Corporation, Syracuse, NY, under Contract No. 68-03-3228. ECAO, U.S. EPA, Cincinnati, OH.

Thomas, J.O., A.J. Cox and F. De Eds. 1957. Kidney cysts produced by diphenylamine. Stanford Med. Bull. 15: 90-93. (Cited in Thomas et al., 1967a).

Thomas, J.O., W.E. Ribelin, R.H. Wilson, D.S. Keppler and F. Deds. 1967a. Chronic toxicity of diphenylamine to rats. Toxicol. Appl. Pharmacol. 10(2): 362-374.

Thomas, J.O., W.E. Ribelin, J.R. Woodward and F. De Eds. 1967b. Chronic toxicity of diphenylamine for dogs. Toxicol. Appl. Pharmacol. 11(1): 184-194.

U.S. EPA. 1982. Health Effects Assessment Summary for 300 Hazardous Organic Constituents in Support of Regulatory Impact Analysis of the Land Disposal Branch (LDB) and Interim Final Incinerator Regulations of the Technical Branch (TB) of the Office of Solid Wastes. Environmental Criteria and Assessment Office, U.S. EPA, Cincinnati, OH.

U.S. EPA. 1984. Summary of Current Acceptable Daily Intakes (ADIs) for Oral Exposure. ECAO-CIN-111. February, 1984. Cincinnati, OH.

U.S. EPA. 1985. Summary of acceptable daily intakes for oral exposure. 5/01/85. ECAO, Cincinnati, OH.